

Title (en)  
METHODS OF INHIBITING RESTENOSIS.

Publication  
**EP 0612249 A4 19951108 (EN)**

Application  
**EP 92924424 A 19921110**

Priority  
• IL 10002391 A 19911111  
• US 9209754 W 19921110  
• US 79032091 A 19911112  
• US 90059292 A 19920618

Abstract (en)  
[origin: WO9309790A1] Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

IPC 1-7  
**A61K 31/70**; **A61K 31/56**; **A61K 31/715**; **A61K 31/735**

IPC 8 full level  
**A61K 31/715** (2006.01); **A61K 31/335** (2006.01); **A61K 31/395** (2006.01); **A61K 31/57** (2006.01); **A61K 31/724** (2006.01); **A61K 31/737** (2006.01); **A61K 38/18** (2006.01); **A61K 47/48** (2006.01); **A61L 15/28** (2006.01); **A61L 26/00** (2006.01); **A61L 27/20** (2006.01); **A61L 27/34** (2006.01); **A61L 27/36** (2006.01); **A61L 27/54** (2006.01); **A61L 33/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/50** (2006.01); **C08B 37/16** (2006.01)

CPC (source: EP)  
**A61K 31/335** (2013.01); **A61K 31/57** (2013.01); **A61K 31/724** (2013.01); **A61K 31/737** (2013.01); **A61K 35/32** (2013.01); **A61K 47/6951** (2017.07); **A61L 15/28** (2013.01); **A61L 26/0023** (2013.01); **A61L 27/20** (2013.01); **A61L 27/34** (2013.01); **A61L 27/3608** (2013.01); **A61L 27/54** (2013.01); **A61L 33/0005** (2013.01); **A61P 43/00** (2017.12); **B82Y 5/00** (2013.01); **C07K 14/50** (2013.01); **C07K 14/503** (2013.01); **C08B 37/0012** (2013.01); **A61L 2300/232** (2013.01); **A61L 2300/414** (2013.01); **A61L 2300/802** (2013.01)

Citation (search report)  
• [X] WO 9002133 A1 19900308 - FORMULATIONS DEV LAB INC [US]  
• [E] EP 0550035 A2 19930707 - KAKEN PHARMA CO LTD [JP]  
• [A] EP 0345660 A1 19891213 - TAKEDA CHEMICAL INDUSTRIES LTD [JP]  
• See references of WO 9309790A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

DOCDB simple family (publication)  
**WO 9309790 A1 19930527**; AU 3074292 A 19930615; AU 678760 B2 19970612; BR 9206736 A 19951031; CA 2124857 A1 19930527; EP 0612249 A1 19940831; EP 0612249 A4 19951108; FI 942166 A0 19940510; FI 942166 A 19940708; JP H07500843 A 19950126; NO 941738 D0 19940510; NO 941738 L 19940711

DOCDB simple family (application)  
**US 9209754 W 19921110**; AU 3074292 A 19921110; BR 9206736 A 19921110; CA 2124857 A 19921110; EP 92924424 A 19921110; FI 942166 A 19940510; JP 50939593 A 19921110; NO 941738 A 19940510